Dataset Information


Discovery of novel therapeutic properties of drugs from transcriptional responses based on multi-label classification.

ABSTRACT: Drug repositioning strategies have improved substantially in recent years. At present, two advances are poised to facilitate new strategies. First, the LINCS project can provide rich transcriptome data that reflect the responses of cells upon exposure to various drugs. Second, machine learning algorithms have been applied successfully in biomedical research. In this paper, we developed a systematic method to discover novel indications for existing drugs by approaching drug repositioning as a multi-label classification task and used a Softmax regression model to predict previously unrecognized therapeutic properties of drugs based on LINCS transcriptome data. This approach to complete the said task has not been achieved in previous studies. By performing in silico comparison, we demonstrated that the proposed Softmax method showed markedly superior performance over those of other methods. Once fully trained, the method showed a training accuracy exceeding 80% and a validation accuracy of approximately 70%. We generated a highly credible set of 98 drugs with high potential to be repositioned for novel therapeutic purposes. Our case studies included zonisamide and brinzolamide, which were originally developed to treat indications of the nervous system and sensory organs, respectively. Both drugs were repurposed to the cardiovascular category.


PROVIDER: S-EPMC5541064 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5349314 | BioStudies
2018-01-01 | S-EPMC5869697 | BioStudies
1000-01-01 | S-EPMC3159979 | BioStudies
2018-01-01 | S-EPMC6231748 | BioStudies
2017-01-01 | S-EPMC5391732 | BioStudies
2011-01-01 | S-EPMC3244383 | BioStudies
2011-01-01 | S-EPMC3502016 | BioStudies
2017-01-01 | S-EPMC5223214 | BioStudies
2017-01-01 | S-EPMC5349249 | BioStudies
2016-01-01 | S-EPMC4884357 | BioStudies